JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Suppr

超能文献

作者信息

Au Wing-Yan, Wan Thomas S K, Ma Edmond S K

出版信息

Int J Hematol. 2013 Mar;97(3):435-7. doi: 10.1007/s12185-013-1287-y. Epub 2013 Feb 7.

DOI:10.1007/s12185-013-1287-y

PMID:23389763

Abstract

摘要

相似文献

JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Int J Hematol. 2013 Mar;97(3):435-7. doi: 10.1007/s12185-013-1287-y. Epub 2013 Feb 7.

Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.

Leukemia. 2007 Aug;21(8):1824-6. doi: 10.1038/sj.leu.2404730. Epub 2007 May 3.

Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.

Int J Lab Hematol. 2013 Feb;35(1):e4-5. doi: 10.1111/ijlh.12010. Epub 2012 Oct 13.

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.

Blood. 2007 May 1;109(9):4106-7. doi: 10.1182/blood-2006-12-061135.

The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.

PLoS One. 2016 Apr 25;11(4):e0154183. doi: 10.1371/journal.pone.0154183. eCollection 2016.

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.

Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.

Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.

Cancer Genet Cytogenet. 2008 Oct;186(1):6-11. doi: 10.1016/j.cancergencyto.2008.04.021.

BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.

J Biol Chem. 2010 Oct 8;285(41):31774-82. doi: 10.1074/jbc.M110.118653. Epub 2010 Jul 27.

Derivative (1)t(1;19)(p13;p13) in the setting of myelofibrosis with JAK2 V617F.

Cancer Genet Cytogenet. 2009 Jun;191(2):109-10. doi: 10.1016/j.cancergencyto.2008.12.015.

[BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].

Rinsho Ketsueki. 2017;58(4):298-302. doi: 10.11406/rinketsu.58.298.

引用本文的文献

CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma.

Oncotarget. 2017 Oct 26;8(66):110052-110063. doi: 10.18632/oncotarget.22123. eCollection 2017 Dec 15.

本文引用的文献

The double jeopardy of clustered measurement and cluster randomisation.

BMJ. 2009 Aug 21;339:b2900. doi: 10.1136/bmj.b2900.

JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.

Leuk Res. 2009 Nov;33(11):e212-3. doi: 10.1016/j.leukres.2009.06.011. Epub 2009 Jul 9.

Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.

Leuk Res. 2008 Oct;32(10):1608-10. doi: 10.1016/j.leukres.2008.03.004. Epub 2008 Apr 29.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Leukemia. 2008 Jul;22(7):1454-5. doi: 10.1038/sj.leu.2405088. Epub 2008 Feb 21.

Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.

Leuk Res. 2008 Jun;32(6):993-5. doi: 10.1016/j.leukres.2007.10.018. Epub 2007 Dec 4.

Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.

Leukemia. 2008 May;22(5):1059-62. doi: 10.1038/sj.leu.2404993. Epub 2007 Nov 1.

Translocation (15;17)(q22;q21) not associated with acute promyelocytic leukemia and negative for PML/RARa rearrangement.

Haematologica. 2000 Jul;85(7):768-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验